Literature DB >> 31211240

Unraveling the cellular heterogeneity of malignant pleural mesothelioma through a deconvolution approach.

Yuna Blum1, Marie-Claude Jaurand2,3, Aurélien De Reyniès1, Didier Jean2,3.   

Abstract

We determined the proportions of epithelioid-like and sarcomatoid-like cellular entities within malignant pleural mesothelioma samples, by deconvolution of their transcriptomes. These proportions are associated with prognosis and may guide therapeutic strategies. This novel approach describes both intra- and inter-tumor heterogeneity and provides a new way of thinking about cancer pathology.

Entities:  

Keywords:  Mesothelioma; deconvolution method; molecular classification; molecular component; tumor heterogeneity

Year:  2019        PMID： 31211240      PMCID： PMC6548486          DOI： 10.1080/23723556.2019.1610322

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

Review 1.  Molecular changes in mesothelioma with an impact on prognosis and treatment.

Authors:  Didier Jean; Julien Daubriac; Françoise Le Pimpec-Barthes; Françoise Galateau-Salle; Marie-Claude Jaurand
Journal:  Arch Pathol Lab Med       Date:  2012-03       Impact factor: 5.534

2.  Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations.

Authors:  Raphael Bueno; Eric W Stawiski; Leonard D Goldstein; Steffen Durinck; Assunta De Rienzo; Zora Modrusan; Florian Gnad; Thong T Nguyen; Bijay S Jaiswal; Lucian R Chirieac; Daniele Sciaranghella; Nhien Dao; Corinne E Gustafson; Kiara J Munir; Jason A Hackney; Amitabha Chaudhuri; Ravi Gupta; Joseph Guillory; Karen Toy; Connie Ha; Ying-Jiun Chen; Jeremy Stinson; Subhra Chaudhuri; Na Zhang; Thomas D Wu; David J Sugarbaker; Frederic J de Sauvage; William G Richards; Somasekar Seshagiri
Journal:  Nat Genet       Date:  2016-02-29       Impact factor: 38.330

3.  Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.

Authors:  Aurélien de Reyniès; Marie-Claude Jaurand; Annie Renier; Gabrielle Couchy; Ilir Hysi; Nabila Elarouci; Françoise Galateau-Sallé; Marie-Christine Copin; Paul Hofman; Aurélie Cazes; Pascal Andujar; Sandrine Imbeaud; Fabien Petel; Jean-Claude Pairon; Francoise Le Pimpec-Barthes; Jessica Zucman-Rossi; Didier Jean
Journal:  Clin Cancer Res       Date:  2014-01-17       Impact factor: 12.531

Review 4.  Novel therapies for malignant pleural mesothelioma.

Authors:  Arnaud Scherpereel; Frederic Wallyn; Steven M Albelda; Camille Munck
Journal:  Lancet Oncol       Date:  2018-03       Impact factor: 41.316

5.  The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma.

Authors:  Bibhusal Thapa; Adriana Salcedo; Xihui Lin; Marzena Walkiewicz; Carmel Murone; Malaka Ameratunga; Khashyar Asadi; Siddhartha Deb; Stephen Arthur Barnett; Simon Knight; Paul Mitchell; D Neil Watkins; Paul C Boutros; Thomas John
Journal:  J Thorac Oncol       Date:  2017-02-28       Impact factor: 15.609

6.  Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group.

Authors:  Aliya N Husain; Thomas Colby; Nelson Ordonez; Thomas Krausz; Richard Attanoos; Mary Beth Beasley; Alain C Borczuk; Kelly Butnor; Philip T Cagle; Lucian R Chirieac; Andrew Churg; Sanja Dacic; Armando Fraire; Francoise Galateau-Salle; Allen Gibbs; Allen Gown; Samuel Hammar; Leslie Litzky; Alberto M Marchevsky; Andrew G Nicholson; Victor Roggli; William D Travis; Mark Wick
Journal:  Arch Pathol Lab Med       Date:  2012-08-28       Impact factor: 5.534

7.  Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.

Authors:  Arnaud Scherpereel; Julien Mazieres; Laurent Greillier; Sylvie Lantuejoul; Pascal Dô; Olivier Bylicki; Isabelle Monnet; Romain Corre; Clarisse Audigier-Valette; Myriam Locatelli-Sanchez; Olivier Molinier; Florian Guisier; Thierry Urban; Catherine Ligeza-Poisson; David Planchard; Elodie Amour; Franck Morin; Denis Moro-Sibilot; Gérard Zalcman
Journal:  Lancet Oncol       Date:  2019-01-16       Impact factor: 41.316

8.  Integrative Molecular Characterization of Malignant Pleural Mesothelioma.

Authors:  Julija Hmeljak; Francisco Sanchez-Vega; Katherine A Hoadley; Juliann Shih; Chip Stewart; David Heiman; Patrick Tarpey; Ludmila Danilova; Esther Drill; Ewan A Gibb; Reanne Bowlby; Rupa Kanchi; Hatice U Osmanbeyoglu; Yoshitaka Sekido; Jumpei Takeshita; Yulia Newton; Kiley Graim; Manaswi Gupta; Carl M Gay; Lixia Diao; David L Gibbs; Vesteinn Thorsson; Lisa Iype; Havish Kantheti; David T Severson; Gloria Ravegnini; Patrice Desmeules; Achim A Jungbluth; William D Travis; Sanja Dacic; Lucian R Chirieac; Françoise Galateau-Sallé; Junya Fujimoto; Aliya N Husain; Henrique C Silveira; Valerie W Rusch; Robert C Rintoul; Harvey Pass; Hedy Kindler; Marjorie G Zauderer; David J Kwiatkowski; Raphael Bueno; Anne S Tsao; Jenette Creaney; Tara Lichtenberg; Kristen Leraas; Jay Bowen; Ina Felau; Jean Claude Zenklusen; Rehan Akbani; Andrew D Cherniack; Lauren A Byers; Michael S Noble; Jonathan A Fletcher; A Gordon Robertson; Ronglai Shen; Hiroyuki Aburatani; Bruce W Robinson; Peter Campbell; Marc Ladanyi
Journal:  Cancer Discov       Date:  2018-10-15       Impact factor: 39.397

Review 9.  Heterogeneity in Malignant Pleural Mesothelioma.

Authors:  Kathrin Oehl; Bart Vrugt; Isabelle Opitz; Mayura Meerang
Journal:  Int J Mol Sci       Date:  2018-05-30       Impact factor: 5.923

10.  Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications.

Authors:  Yuna Blum; Clément Meiller; Lisa Quetel; Nabila Elarouci; Mira Ayadi; Danisa Tashtanbaeva; Lucile Armenoult; François Montagne; Robin Tranchant; Annie Renier; Leanne de Koning; Marie-Christine Copin; Paul Hofman; Véronique Hofman; Henri Porte; Françoise Le Pimpec-Barthes; Jessica Zucman-Rossi; Marie-Claude Jaurand; Aurélien de Reyniès; Didier Jean
Journal:  Nat Commun       Date:  2019-03-22       Impact factor: 14.919
  10 in total
  3 in total

Review 1.  Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma.

Authors:  Steven G Gray
Journal:  BMC Pulm Med       Date:  2021-05-05       Impact factor: 3.317

Review 2.  The Biology of Malignant Mesothelioma and the Relevance of Preclinical Models.

Authors:  Christophe Blanquart; Marie-Claude Jaurand; Didier Jean
Journal:  Front Oncol       Date:  2020-03-25       Impact factor: 6.244

Review 3.  Malignant Pleural Mesothelioma: Genetic and Microenviromental Heterogeneity as an Unexpected Reading Frame and Therapeutic Challenge.

Authors:  David Michael Abbott; Chandra Bortolotto; Silvia Benvenuti; Andrea Lancia; Andrea Riccardo Filippi; Giulia Maria Stella
Journal:  Cancers (Basel)       Date:  2020-05-07       Impact factor: 6.639
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.